| Bioactivity | Tamrintamab (SC-003 mAb, SC-Mab003, SC34.28ss1) is an ADC Antibody targeting to dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research[1][2]. |
| Invitro | Tamrintamab 是一种通过蛋白酶可裂解的马来酰亚胺接头靶向二肽酶 3 (DPEP3 或 MBD3) 的单克隆抗体[1]。 |
| Name | Tamrintamab |
| CAS | 2148325-59-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Martín-Sabroso C, et al. Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives. Pharmaceutics. 2021 Oct 15;13(10):1705. [2]. Wiedemeyer W R, et al. Abstract NT-113: SC-003, AN ANTIBODY-DRUG CONJUGATE TARGETING DIPEPTIDASE 3, EXHIBITS POTENT ANTI-TUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF HIGH GRADE SEROUS OVARIAN CANCER[J]. Clinical Cancer Research, 2019, 25(22_Supplement): NT-113-NT-113. |